Skip to main content

Table 2 In-hospital events and treatment strategy

From: Clinical outcomes associated with catecholamine use in patients diagnosed with Takotsubo cardiomyopathy

Variables No catecholamines
(n = 93)
catecholamines
(n = 21)
p value*
Life-threatening arrhythmia 6 (6.45) 7 (33.33) < 0.01
NPPV and intubation 21 (22.5) 18 (85.7) < 0.01
Resuscitation 3 (3.22) 6 (28.57) < 0.01
Defibrillator-Implantation 1 (1.0) 1 (4.7) 0.33
VA-ECMO 0 (0) 1 (4.7) 0.18
Admission to ICU, length of stay 3.24 ± 3.59 9.57 ± 11.32 < 0.01
In-hospital death 3 (3.2) 6 (28.5) < 0.01
Thromboembolic events 10 (10.75) 4 (19.04) 0.29
Acquired Long QTs 61 (65.59) 12 (57.14) 0.41
Cardiogenic Shock 4 (4.30) 18 (85.71) < 0.01
  1. *p values for the comparison between no catecholamines and catecholamines; NPPV Noninvasive positive pressure ventilation, VA-ECMO Veno-arterial extracorporal membrane oxygenation, ICU Intermediate care unit
  2. The bolded indication highlight significant values